Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244228 | 0.83 | KMT2A (0.53) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL4244230 | 0.81 | POLB (0.54) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL2251568 | 0.80 | CYP19A1 (0.42) | CYP19A1NAMPTALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL2945515 | 0.79 | ALDH1A1 (0.64) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL28997377 | 0.79 | POLB (0.53) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL3292568 | 0.79 | ALDH1A1 (0.64) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL112785 | 0.79 | CYP19A1 (0.50) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| SCHEMBL1696 | 0.78 | ALDH1A1 (0.63) | KMT2AALDH1A1LMNATDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28059064 | 0.78 | ALDH1A1 (0.62) | CYP19A1KMT2ACYP17A1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL7601456 | 0.78 | CYP19A1 (0.49) | CYP19A1KMT2ACYP17A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | claimed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | claimed |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CYP19A1 3259/4885KMT2A 4445/4885CYP17A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.